Meropenem Eberth

Meropenem, the active ingredient in Meropenem Eberth, is a carbapenem antibiotic presented as a sterile powder for injection for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, nosocomial pneumonia, meningitis, and septic shock in hospitalized patients.

GNH USA supplies Meropenem Eberth as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance, and on‑time delivery to meet urgent clinical needs.

Meropenem is a broad‑spectrum carbapenem antibiotic used to treat serious bacterial infections in hospitalized patients.

- Complicated intra‑abdominal infections: provides rapid bacterial eradication and improves clinical outcomes in patients with intra‑abdominal sepsis. - Complicated urinary tract infections: eliminates resistant uropathogens and resolves infection in complicated cystitis and pyelonephritis. - Nosocomial pneumonia: effective against multidrug‑resistant organisms causing hospital‑acquired lung infections. - Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis caused by susceptible strains. - Severe sepsis and septic shock: offers broad coverage for Gram‑negative and Gram‑positive pathogens in critical care settings.

Adverse reactions to meropenem may vary in frequency and severity.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring in many patients. - Diarrhea: loose stools that are usually self‑limiting. - Rash: skin erythema or pruritus without systemic involvement. - Injection site pain: discomfort at the intravenous infusion site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or high doses. - Clostridioides difficile colitis: severe diarrhea due to overgrowth of toxin‑producing bacteria. - Anaphylaxis: acute, potentially life‑threatening allergic reaction. - Hepatic failure: rare but serious liver enzyme elevation and dysfunction.

When using meropenem, clinicians should consider several precautionary measures to ensure safe therapy.

- Renal function: adjust dose in patients with impaired renal clearance to avoid accumulation. - Allergy: avoid in individuals with known hypersensitivity to carbapenems or other β‑lactam antibiotics. - Seizure risk: monitor patients with central nervous system disorders or receiving high‑dose therapy. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Superinfection: be aware of possible overgrowth of fungi or Clostridioides difficile during treatment. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Valproic acid: reduces plasma concentrations, potentially precipitating seizures. - Probenecid: may increase meropenem levels, raising the risk of toxicity. - High‑dose CNS stimulants: can heighten seizure risk when combined with meropenem.

Moderate Interactions (Monitor Closely): - Aminoglycosides: additive nephrotoxicity; monitor renal function. - Loop diuretics: may enhance renal toxicity; assess kidney parameters. - Anticoagulants (e.g., warfarin): monitor INR as meropenem can alter anticoagulant effect.